Program
AG-236
A development code.
Its studies are mostly in Polycythemia Vera, led by Agios Pharmaceuticals.
Furthest: phase 3, since Sep 30, 20262 company-led studies, 2 open or runningNext primary completion: Aug 2030 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticals | 22 open or running | phase 3since Sep 30, 2026 | Jul 11, 2025 | Aug 2030phase 3 · NCT07859423 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 11, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT07075640 · 24 enrolled · United States
- Sep 30, 2026Phase 3 study in Polycythemia VeraPhase 3 reachedNCT07859423 · 245 planned
Ahead
- Aug 2030Primary completion: phase 3 study in Polycythemia VeraNCT07859423
TargetBeta
TMPRSS6 →read by rule
“AG-236 is a small interfering ribonucleic acid (siRNA) targeting transmembrane serine protease 6 (TMPRSS6) intended for the treatment of PV.”study text, by rule · the study
Other programs on TMPRSS6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sapablursenrule | Ionis Pharmaceuticals | phase 3 | 4 |
| Anti-TMPRSS6 Monoclonal Antibody DISC-3405rule | disc-medicine-inc | phase 2 | 6 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07859423Polycythemia Vera | 3 | Not yet recruiting | Aug 2030 | 245 |
| NCT07075640Healthy Participants · United States | 1 | Active, not recruiting | Feb 11, 2026 | 24 |
How it is read
Names in the registry
- “AG-236”, 2 entries
Codes read as this program: AG236.
Conditions, from the studies’ own filings
- Polycythemia Vera, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.